News
Arrowhead Pharma Kicks Off Phase III Trial for Zodasiran in Homozygous Familial Hypercholesterolemia
The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback